Results 51 to 60 of about 25,818 (186)

The Evolution of Pneumocystis jirovecii Pneumonia Prophylaxis for Pediatric Patients With Extracranial Solid Tumors: A Review of Historical Insights and Future Directions

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Pneumocystis jirovecii pneumonia (PJP) remains a modern‐day complication for pediatric patients receiving treatment for extracranial solid tumors (ST), highlighting the need for reconsideration of our current approach toward PJP prophylaxis. This critical review aims to evaluate both universal and risk‐stratified approaches to PJP prophylaxis ...
Kriti Kumar, Denise M. Connolly, Ellen Kellington, Elyse Zelunka, Karla Kerrigan, Furqan Shaikh, Paul C. Nathan, Meredith S. Irwin, Sarah Cohen‐Gogo   +8 more
wiley   +1 more source

Real World Experience of Crizotinib in 104 Patients With ALK Rearrangement Non-small-cell Lung Cancer in a Single Chinese Cancer Center

Frontiers in Oncology, 2019
Purpose: Our study aimed to provide data on effectiveness, safety of crizotinib treatment, brain metastases, progression patterns, and sequential therapy beyond crizotinib treatment in patients with advanced ALK-positive NSCLC in China.Methods: We ...
Chang Liu, Chang Liu, Hui Yu, Hui Yu, Qianqian Long, Qianqian Long, Haiquan Chen, Haiquan Chen, Yuan Li, Yuan Li, Weixin Zhao, Weixin Zhao, Kuaile Zhao, Kuaile Zhao, Zhengfei Zhu, Zhengfei Zhu, Si Sun, Si Sun, Min Fan, Min Fan, Jianhua Chang, Jianhua Chang, Jialei Wang, Jialei Wang   +23 more
doaj   +1 more source

Autocrine Activation of the MET Receptor Tyrosine Kinase in Acute Myeloid Leukemia [PDF]

, 2012
Although the treatment of acute myeloid leukemia (AML) has improved significantly, more than half of all patients develop disease that is refractory to intensive chemotherapy.
A Burnett, A Thomas Look, Alex Kentsis, Amanda Christie, Andrew L Kung, AW Whitehurst, C Birchmeier, C Scholl, C Wang, Casie Reed, D Grimwade, DR Robinson, Eleni Tholouli, George Vande Woude, HY Zou, J Zhou, James G Christensen, Jeffery L Kutok, Jonathan D Licht, Kim L Rice, Lisa A Moreau, Louis M Staudt, M Mohammadi, MB Sporn, MM Loriaux, NC Turner, P Mathew, Peter J M Valk, PJ Valk, R Bernards, R Haq, R Majeti, R Zheng, Richard J Byers, Ruud Delwel, S Heinrichs, SA Armstrong, Scott J Rodig, Suzanne E Dahlberg, T Sato, Takaomi Sanda, TF Westbrook, TL Gu, VN Ngo, VN Ngo, Vu Ngo   +45 more
core   +1 more source

A case of ROS1‐rearranged lung adenocarcinoma in a young man with multiple serosal effusions: Diagnostic pitfalls in pericardial fluid cytology

Precision Medical Sciences, EarlyView.
Abstract ROS1‐rearranged lung adenocarcinoma is a rare subset of non‐small‐cell lung cancer, typically occurring in young never‐smokers. Its occurrence in very young men with a fluid‐dominant presentation is unusual and may lead to diagnostic pitfalls.
Thanh Thao Nguyen, Marie Kawakami, Yoshiiku Okanemasa, Yumi Tsubata, Sohsuke Yamada   +4 more
wiley   +1 more source

First‐line crizotinib versus platinum‐pemetrexed chemotherapy in patients with advanced ROS1‐rearranged non‐small‐cell lung cancer

Cancer Medicine, 2020
Objectives Food and Drug Administration (FDA) approved crizotinib for advanced ROS1‐rearranged (ROS1+) non‐small‐cell lung cancer (NSCLC) patients due to a single‐arm study PROFILE 1001.
Lan Shen, Tan Qiang, Ziming Li, Ding Ding, Yongfeng Yu, Shun Lu   +5 more
doaj   +1 more source

LINC01001 Promotes Progression of Crizotinib-Resistant NSCLC by Modulating IGF2BP2/MYC Axis

Frontiers in Pharmacology, 2021
Background: Crizotinib is a microtubule-related protein-4-anaplastic lymphoma kinase (EML4-ALK) multi-target tyrosine kinase inhibitor applied in the treatment of ALK-rearranged NSCLC.
Meiling Zhang, Qian Wang, Zihao Ke, Yijing Liu, Huijin Guo, Shencun Fang, Kaihua Lu   +6 more
doaj   +1 more source

Phytochemical‐Based Strategies for Lung Cancer: Clinical Insights Into Pleiotropic Molecular Signaling and Therapeutic Roles

Phytotherapy Research, EarlyView.
Lung cancer (LC) remains the leading cause of global cancer‐related death. Phytochemicals from medicinal plants are increasingly being considered as potential LC treatment agents due to their multi‐targeted action, safety, and accessibility. These have anticancer properties by regulating key molecular signaling pathways.
Md. Rezaul Islam, Abdur Rauf, Happy Akter, Md. Ibrahim Khalil Al‐Imran, Md. Naeem Hossain Fakir, Gazi Kaifeara Thufa, Umme Habiba, Karjin Nahar Riya, Md. Mahfuzur Rahman, Md Sadique Hussain, Hanan A. Ogaly, Abdullah S. M. Aljohani, Waleed Al Abdulmonem, Dorota Formanowicz, Marcello Iriti   +14 more
wiley   +1 more source

Crizotinib and its enantiomer suppress ferroptosis by decreasing PE-O-PUFA content

Cell Death Discovery
Ferroptosis is a specific form of cell death characterized by excessive accumulation of cellular lipid peroxides. Ferroptosis is closely associated with various diseases, inhibition of which may help alleviate multi-organ injury caused by ischemia ...
Si-Yu Cen, Fang Lin, Xuan Li, Yanglin Hu, Jin-Pin Liu, Zian Xue, Yun Gao, Yi-Ping Sun, Sanyong Zhu, Yongjun Dang, Yahui Zhao, Hai-Xin Yuan   +11 more
doaj   +1 more source

Clinical Efficacy of Crizotinib in Advanced ALK Positive 
Non-small Cell Lung Cancer

Chinese Journal of Lung Cancer, 2015
Background and objective The aim of this study is to explore clinical efficacy of crizotinib in advanced anaplastic lymphoma kinase (ALK) positive non-small cell lung cancer.
Jing ZHAO, Kun ZHANG, Liyu ZHANG, Hong WANG   +3 more
doaj   +1 more source

(S)-crizotinib induces apoptosis in human non-small cell lung cancer cells by activating ROS independent of MTH1

Journal of Experimental & Clinical Cancer Research, 2017
Background Non–small cell lung cancer (NSCLC) accounts for approximately 80–85% of all lung cancers and is usually diagnosed at an advanced stage with poor prognosis. Targeted therapy has produced unprecedented outcomes in patients with NSCLC as a number
Xuanxuan Dai, Guilong Guo, Peng Zou, Ri Cui, Weiqian Chen, Xi Chen, Changtian Yin, Wei He, Rajamanickam Vinothkumar, Fan Yang, Xiaohua Zhang, Guang Liang   +11 more
doaj   +1 more source